Although there are no studies in the literature evaluating GAL-3 serum levels in gliomas, there are studies showing increases in different cancers, such as gastric, hepatocellular, ovarian, pancreatic, and colorectal, compared with controls [36–40]. This evidence concerns the gene LGALS3 and central nervous system cancer.